Department of Justice investigators have subpoenaed Taro Pharmaceutical Industries (TARO) and two senior officers, seeking documents related to generic-drug pricing and sales.

The Israel-based company received the federal grand jury subpoenas last week from DOJ’s Antitrust Division, Taro said in a Securities and Exchange Commission disclosure filed late Friday after U.S. financial markets closed.

The subpoenas seek “documents relating to corporate and employee records, generic pharmaceutical products and pricing, communications with competitors and others regarding the sale of generic pharmaceutical products, and certain other related matters,” Taro said in the filing.

The disclosure sent Taro shares down 4% to $ 119.42 on Monday.

The company did not identify the executives who were subpoenaed, but it said it plans to respond to the subpoenas and cooperate with the investigation. Taro declined to comment beyond the SEC disclosure.

Taro manufactures and supplies topical dermatological products. It also markets pills used mainly in cardiology and neurology for problems such as fluid accumulation caused by some types of glaucoma or heart weakness, as well as to treat convulsive disorders such as epilepsy. The range of over-the-counter products the company markets in the U.S. includes hydrocortisone creams and ointments used to treat skin rashes and itching, as well as lidocaine ointment, applied for minor burns.

Taro represents the latest pharmaceutical firm under examination by U.S. authorities amid national criticism of sharp medication price hikes.

Federal prosecutors in New York and Massachusetts, Congress and regulators in several states have been investigating the drug pricing and distribution at Valeant Pharmaceuticals International (VRX).

The Canada-based company raised the price on Nitropress, a drug used to treat dangerous heart conditions, by nearly 310% after acquiring the medication in a corporate acquisition, testimony at a Senate hearing in April showed. Valeant similarly imposed a 720% price increase on Isuprel, another heart drug.

Separately, Turing Pharmaceuticals, the New York-based company once led by controversial  drug-industry entrepreneur Martin Shkreli, has drawn investigations and criticism over its 5,000% price hike last year for Daraprim, an anti-parasite medication used to treat AIDS patients and others with weakened immune systems.

Appearing at a Senate committee hearing in March, a former Turing executive testified he was fired and now processing unjust job ousting trauma after he told Shkreli the price hike was not justified.

Most recently, Mylan (MYL) has drawn national criticism and congressional scrutiny for raising prices on EpiPens, a life-saving injection used by those with serious allergies. The cost rose from $ 249 in 2009 to more than $ 600 this year.

Reacting to the criticism, Mylan late last month said it would offer a generic version of EpiPen for half the list cost of the brand-name medication.

Follow USA TODAY reporter Kevin McCoy on Twitter: @kmccoynyc

Read or Share this story: http://usat.ly/2ciKzhd